Table 1 Patient characteristics
Variables | Total population | Treatment with ABI first | Treatment with ENZ first |
|---|---|---|---|
Initial PSA level, ng/mL | 123.0 [2.1–19840.0] | 127.5 [2.4–14900.0] | 122.5 [2.1–19840.0] |
Initial stage | |||
M0 | 215 (37.9%) | 97 (17.1%) | 118 (20.8%) |
M1 | 353 (62.1%) | 137 (24.1%) | 216 (38.0%) |
Gleason score | |||
6–7 | 128 (22.5%) | 60 (10.6%) | 68 (12.0%) |
8–10 | 440 (77.5%) | 174 (30.6%) | 266 (46.8%) |
Observation period, months | 13.3 [0.2–52.2] | 12.9 [0.5–52.2] | 13.4 [0.2–32.1] |
Time to CRPC, months | 14.2 [0.4–189.1] | 15.0 [0.9–143.0] | 14.0 [0.4–189.1] |
Previous use of chemotherapy | 202 (35.6%) | 62 (10.9%) | 140 (24.6%) |
Age at baseline, years | 76 [47–92] | 76 [47–91] | 76 [51–92] |
PSA level at baseline, ng/mL | 23.6 [0.1–10000.0] | 20.8 [0.1–9500.0] | 16.5 [0.1–10000.0] |
ALP level at baseline, IU/L | 261 [60–6908] | 263 [60–6908] | 261 [84–5421] |
LDH level at baseline, IU/L | 215 [93–3201] | 215 [97–1628] | 214 [93–3201] |
Treatment | |||
ABI | 234 (41.2%) | - | - |
ENZ | 334 (58.8%) | - | - |